Brainsway (BWAY) has released an update.
BrainsWay, a leader in noninvasive neurostimulation treatments, has reported a 28% year-over-year revenue growth for Q2 2024 and raised the lower end of its full-year 2024 revenue guidance to $38.5-$40 million. The company also announced positive net income for the third consecutive quarter and positive adjusted EBITDA and cash flow from operations for the fourth consecutive quarter, indicating sustained profitability and financial health. These results reflect strong market demand for their Deep TMS system and an expanding international presence, including a new distribution agreement in Canada.
For further insights into BWAY stock, check out TipRanks’ Stock Analysis page.
